Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Dose-Escalation Study of UCART19 in Relapsed/Refractory CD19-Positive B-ALL (CALM)
jRCT1080224971Phase 1Completed
- Sponsor
- Nihon Servier
- Start
- Dec 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 1, open-label, single-arm trial of UCART19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Nihon Servier. Primary endpoints: Maximum tolerated dose (MTD) of UCART19, Recommended dose (RD) of UCART19 and 1 more. Started Dec 2019; status: completed.
02
Drugs
UCART19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on jRCT1080224971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224971.